Zenas BioPharma, Inc.

Zenas BioPharma, Inc. (ZBIO) priced its initial public offering on Sep 13, 2024 at $17.00 per share, within its $16.00–$18.00 range, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $676.5M. Morgan Stanley was lead-left underwriter, joined by Jefferies, Citigroup and Guggenheim. Ropes & Gray advised the company and Cooley advised the underwriters.

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company developing immunology-based therapies for autoimmune diseases. Its strategy combines acquiring product candidates with internal expertise and external resources, in an immunology and inflammation focus.

Status

IPO

Ticker

ZBIO

Exchange

Nasdaq Global Select

Priced

Sep 13, 2024

IPO price

$17.00

Price range

$16.00–$18.00

Market cap at IPO price

$676.5M

First filed

Aug 22, 2024

Underwriters

Morgan Stanley, Jefferies, Citigroup and Guggenheim

Company counsel

Ropes & Gray

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.